A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.
Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacopuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D.
Merz V, et al. Among authors: santoro r.
Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020.
Ther Adv Med Oncol. 2020.
PMID: 32684989
Free PMC article.